-- Lawrence Hurst, M.D., Professor and Chair, Chief of Hand Surgery,
Department of Orthopaedics of the Health Science Center, State University
of New York at Stony Brook
-- Gerald H. Jordan, M.D., F.A.C.S., F.A.A.P., Professor, Department of
Urology, Eastern Virginia Medical School Director, Devine Center for
Genitourinary Reconstructive Surgery, Sentara Norfolk General Hospital
The event will be held from 11:30 a.m. to 3:30 p.m. Eastern Time. To
access the live web cast for the presentation, which will begin at 12:00
p.m. Eastern Time, please log on to the Company's web site at
www.auxilium.com approximately 15 minutes prior to the presentation. The
web cast will also be archived and available on the Company's web site
approximately one hour after completion of the live web cast and will
remain available for approximately 90 days after the event.
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company
with a focus on developing and marketing to urologists, endocrinologists,
orthopedists and select primary care physicians. Auxilium markets Testim®
1%, a topical testosterone gel, for the treatment of hypogonadism, through
its approximately 190-person sales and marketing team. Auxilium has four
projects in clinical development. XIAFLEX™ (clostridial collagenase for
injection), formerly referred to as AA4500, is in phase III of development
for the treatment of Dupuytren's contracture and is in phase II of
development for the treatment of Peyronie's disease and Frozen Shoulder
syndrome (Adhesive Capsulitis). Auxilium's transmucosal film product
candidate for the treatment of overactive bladder (AA4010) is in phase I of
development. The Company is currently seeking a partner to further develop
this product candidate. Auxilium has two pain products using its
transmucosal film delivery system in pre-clinical development. Auxilium has
rights to six additional pain products and products for hormone replacement
and urologic disease using its transmucosal film delivery system. Auxilium
also has options to all indications using XIAFLEX for non-topical
formulations. For additional information, visit http://www.auxilium.com.
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF
1995
This release contains "forward-looking statements" within the meaning of
The Private Securities Litigation Reform Act of 1995, including statements
regarding the future potential commercial opportunities for XIAFLEX, the
Company's intention to webcast the Analyst and Institutional Investor
Meeting and the Company's products in development for Dupuytren's
contracture, Peyronie's disease, Frozen Shoulder syndrome, overactive
bladder, pain, hormone replacement and urologic disease. All statements
other than statements of historical facts contained in this release,
including but not limited to, statements regarding future expectations,
plans and prospects for the Company, statements regarding forward-looking
financial information and other statements containing the words "believe,"
"may," "could," "will," "estimate," "continue," "anticipate," "intend,"
"should," "plan," "expect," and similar expressions, as they relate to the
Company, constitute forward-looking statements. Actual results may differ
materially from those reflected in these forward-looking statements due to
various factors, including general financial, economic, regulatory and
political conditions affecting the biotechnology and pharmaceutical
industries and those discussed in the Company's Annual Report on Form 10-K
for the year ended December 31, 2006 and in the Company's Quarterly Report
on Form 10-Q for the period ended June 30, 2007 under the heading "Risk
Factors," which are on file with the Securities and Exchange Commission
(the "SEC") and may be accessed electronically by means of the SEC's home
page on the Internet at http://www.sec.gov or by means of the Company's
home page on the Internet at http://www.auxilium.com under the heading
"Investor Relations -- SEC Filings." There may be additional risks that the
Company does not presently know or that the Company currently believes are
immaterial which could also cause actual results to differ from those
contained in the forward-looking statements. Given these risks and
uncertainties, any or all of these forward-looking statements may prove to
be incorrect. Therefore, you should not rely on any such factors or
forward-looking statements.
In addition, forward-looking statements provide the Company's expectations,
plans or forecasts of future events and views as of the date of this
release. The Company anticipates that subsequent events and developments
will cause the Company's assessments to change. However, while the Company
may elect to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the
Company's assessments as of any date subsequent to the date of this
release.
Contact Information: For More Information, Contact: James E. Fickenscher Chief Financial Officer Auxilium Pharmaceuticals, Inc. (484) 321-5900 Gregory Gin Lazar Partners, Ltd. (212) 867-1762